Fibromyalgia and the peptide conversation — beyond duloxetine and pregabalin

This is fibromyalgia — and its defining feature isn't a damaged joint or an inflamed tissue or a lesion that shows up on imaging. It's a nervous system problem. The pain is real and the suffering is real, but the origin is not where the pain is felt. It's in how the brain and spinal cord process pain signals — a process called central sensitization, in which the pain amplification system gets calibrated too high and stays there.

The conventional management framework for fibromyalgia involves a few different levers. SNRIs like duloxetine (Cymbalta) are FDA-approved for fibromyalgia and work partly by modulating descending pain inhibition pathways in the central nervous system. Pregabalin (Lyrica) is also FDA-approved for fibromyalgia and works by reducing the excitability of pain-signaling neurons. Both can be helpful for some patients and are poorly tolerated or insufficiently effective for others. Cognitive behavioral therapy — specifically CBT adapted for chronic pain — has meaningful evidence behind it and changes how the nervous system relates to pain signals over time. Graded exercise, approached carefully and in a form that doesn't overwhelm the system, has demonstrated benefit. Low-dose naltrexone — not FDA-approved for fibromyalgia but widely used off-label — has shown results in small trials and has a favorable safety profile that has made it a common adjunct in fibromyalgia management. The management picture for fibromyalgia is genuinely multi-modal, because there is no single upstream driver that a single drug can fix.

Why not? Because central sensitization isn't one thing. It's a state the nervous system arrives at through multiple converging pathways — peripheral inflammation feeding chronic input to the central pain system, autonomic dysregulation keeping the system in a state of heightened threat-detection, sleep disruption preventing the nightly recalibration that would normally reset pain thresholds, immune dysregulation maintaining a low-grade inflammatory environment, and psychological stress keeping the nervous system's threat appraisal elevated. These aren't separate conditions sitting alongside fibromyalgia. They're parts of the mechanism. Which is why treatment that addresses only one of them is usually incomplete.

The sleep question in fibromyalgia deserves particular attention because it's more specific than just "poor sleep makes pain worse," which is true but incomplete. Fibromyalgia is associated with disruption of slow-wave sleep — the deepest, most physically restorative stage of the sleep cycle. Studies using polysomnography have found that fibromyalgia patients show intrusion of alpha-wave activity into slow-wave sleep, a phenomenon that can produce hours in bed that don't result in physical restoration. The pain system, it turns out, is not separate from sleep architecture. Slow-wave sleep is when the glymphatic system clears inflammatory metabolites from the brain, when growth hormone pulses to drive cellular repair, and when the pain regulation circuits that were overloaded during the day have the opportunity to recalibrate. When that phase is disrupted — even without conscious awareness that the sleep is non-restorative — the pain amplification system runs hotter the following day. This is the fibromyalgia-sleep loop: pain disrupts slow-wave, disrupted slow-wave amplifies pain.

This is the mechanistic context in which growth hormone secretagogues like Sermorelin become relevant to fibromyalgia discussions, not as a pain treatment per se but as an intervention in the sleep-architecture side of the loop. Sermorelin stimulates the pituitary to increase its own production of growth hormone, using the body's natural regulatory feedback mechanisms rather than supplying exogenous hormone. The evidence base for Sermorelin in fibromyalgia specifically is limited — there have been small studies suggesting a relationship between growth hormone deficiency and fibromyalgia, and clinical observations of symptom improvement in some patients when GH physiology is supported, but this is not a primary or established treatment pathway. It's a mechanistic hypothesis that a specialist might explore in the right clinical context, not a first-line intervention. Honest framing matters here: the research is preliminary and the clinical application is off-label.

BPC-157's potential relevance to fibromyalgia enters through a different door. Fibromyalgia frequently coexists with tissue-level complaints — muscle tension, myofascial pain, gut symptoms (irritable bowel syndrome overlaps with fibromyalgia at remarkably high rates, estimated at 30–70% depending on the study), and a general sense of physical fragility. BPC-157 is a synthetic peptide derived from a protective protein in gastric juice, studied primarily in animal models for its effects on tissue healing, gut mucosal repair, and anti-inflammatory activity. The human evidence for BPC-157 is limited and the long-term safety profile in humans isn't well characterized. But the mechanistic case for its relevance to the gut component of fibromyalgia — and to the general inflammatory environment that may be feeding central sensitization — is plausible enough that it has entered the conversation in functional and integrative medicine settings. It is not a fibromyalgia treatment. It is a research compound with mechanisms that may be relevant to aspects of the condition.

Vasoactive intestinal peptide — VIP — has an interesting intersection with fibromyalgia through both the autonomic dysregulation and the immune regulation angles. Autonomic nervous system dysfunction is well-documented in fibromyalgia: dysregulated sympathetic-parasympathetic balance, abnormal heart rate variability, impaired autonomic responses to orthostatic stress. VIP functions as a neuromodulator across both the enteric nervous system and the central nervous system, and has demonstrated anti-inflammatory and mast-cell-modulating effects in research contexts. The hypothesis that VIP deficiency or dysregulation might be contributing to autonomic dysfunction in fibromyalgia patients is biologically coherent. The clinical evidence in fibromyalgia specifically is minimal. This is a mechanistic thread rather than an established clinical application.

Selank enters the fibromyalgia conversation through the anxiety-pain coupling that is one of the more important and underappreciated features of central sensitization. Pain and anxiety are not separate experiences processed by separate neural systems. They share circuitry — the anterior cingulate cortex, the insula, the amygdala, the descending inhibitory pathways. Anxiety amplifies pain perception, and chronic pain elevates anxiety, and the resulting feedback loop is a significant driver of fibromyalgia's persistence. Selank, a synthetic analog of tuftsin researched for its anxiolytic properties and effects on neuropeptide Y, has been studied primarily in Russian research contexts for anxiety and stress conditions, with limited Western replication. The hypothesis is that modulating the anxiety-nervous-system component could, in a subset of fibromyalgia patients, reduce the neural amplification feeding the pain signal. This is a hypothesis with biological coherence and limited clinical trial evidence.

Thymosin Alpha-1's relevance in fibromyalgia is the most speculative of these threads. There is an inflammatory hypothesis for fibromyalgia — elevated cytokines, microglial activation in pain-processing regions, a low-grade neuroinflammatory state — that would make immune normalization mechanistically relevant. Whether Thymosin Alpha-1's immune-regulatory effects translate to clinical improvement in fibromyalgia is not established by current evidence. It remains a thread that researchers and some clinicians follow rather than a demonstrated application.

What all of these peptide conversations share is a common limitation: fibromyalgia lacks the clear upstream driver that would let you identify which pathway is most relevant for a specific patient. Central sensitization is the final common pathway through which multiple different initial causes can produce similar symptom pictures. Without knowing what's feeding the sensitization in your particular case — whether it's sleep disruption, autonomic dysfunction, gut dysbiosis, low-grade neuroinflammation, psychological stress, a combination — choosing peptide interventions is more like casting into the dark than targeted treatment.

The foundational interventions have real evidence behind them and they come first. Sleep architecture — specifically the slow-wave disruption issue — is worth addressing directly, whether through behavioral sleep medicine, CBT for insomnia, or evaluation for sleep-disordered breathing that may be making the architecture worse. Graded exercise appropriate to current tolerance, because even in fibromyalgia where exercise can flare symptoms, carefully calibrated movement changes pain-regulation circuits over time. Stress regulation — not because fibromyalgia is a stress disorder, but because chronic sympathetic activation is a direct input to central sensitization. Gut health, given the IBS overlap. These aren't alternatives to pharmacological or peptide approaches; they're the platform on which those approaches can actually work.

Pain management specialists and rheumatologists with specific fibromyalgia experience are the appropriate starting point for evaluation. Fibromyalgia is a condition where the clinical relationship and the treatment philosophy matter enormously — patients who are met with dismissal or told that nothing structural is wrong therefore nothing is wrong have worse outcomes than those treated within a model that takes central sensitization seriously as a physiological mechanism. The right specialist frames fibromyalgia not as a mystery but as a nervous system condition with identifiable mechanisms and targeted intervention points. That framing is the beginning of treatment, not just the backdrop to it.

Any peptide conversation happens within a specialist-supervised framework, after the foundational work has been addressed, and with honest expectations about what preliminary evidence can support. This is a condition where the complexity is real and the nuance is non-negotiable.